Indalpine

Identification

Name
Indalpine
Accession Number
DB08953
Type
Small Molecule
Groups
Investigational, Withdrawn
Description

Indalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.

Structure
Thumb
Synonyms
Not Available
External IDs
LM-5008
International/Other Brands
Upstène (Pharmuka)
Categories
UNII
V35562QSVT
CAS number
63758-79-2
Weight
Average: 228.3327
Monoisotopic: 228.16264865
Chemical Formula
C15H20N2
InChI Key
SADQVAVFGNTEOD-UHFFFAOYSA-N
InChI
InChI=1S/C15H20N2/c1-2-4-15-14(3-1)13(11-17-15)6-5-12-7-9-16-10-8-12/h1-4,11-12,16-17H,5-10H2
IUPAC Name
3-[2-(piperidin-4-yl)ethyl]-1H-indole
SMILES
C(CC1=CNC2=CC=CC=C12)C1CCNCC1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Indalpine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Indalpine.Experimental
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Indalpine.Approved
AcenocoumarolIndalpine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Indalpine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Indalpine.Approved
Acetylsalicylic acidIndalpine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Indalpine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Indalpine.Approved, Investigational
AlaproclateIndalpine may increase the serotonergic activities of Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Indalpine.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Indalpine.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Indalpine.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Indalpine.Investigational
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Indalpine.Experimental, Illicit
AlphaprodineAlphaprodine may increase the serotonergic activities of Indalpine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Indalpine.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Indalpine.Approved, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Indalpine.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Indalpine.Approved, Illicit
AmoxapineIndalpine may increase the serotonergic activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Indalpine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Indalpine is combined with Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Indalpine.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Indalpine.Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Indalpine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Indalpine.Approved
AtenololThe serum concentration of Atenolol can be increased when it is combined with Indalpine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Indalpine.Investigational, Vet Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Indalpine.Illicit
BefunololThe serum concentration of Befunolol can be increased when it is combined with Indalpine.Experimental
BendroflumethiazideIndalpine may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Indalpine.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Indalpine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Indalpine.Approved
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Indalpine.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Indalpine.Approved, Investigational
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Indalpine.Approved
BezitramideBezitramide may increase the serotonergic activities of Indalpine.Experimental, Illicit, Withdrawn
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Indalpine.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Indalpine.Investigational
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Indalpine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Indalpine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Indalpine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Indalpine.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Indalpine.Investigational
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Indalpine.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Indalpine.Investigational
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Indalpine.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Indalpine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Indalpine.Approved
BuprenorphineBuprenorphine may increase the serotonergic activities of Indalpine.Approved, Illicit, Investigational, Vet Approved
BuspironeBuspirone may increase the serotonergic activities of Indalpine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Indalpine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Indalpine.Vet Approved
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Indalpine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Indalpine.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Indalpine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Indalpine.Investigational
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Indalpine.Approved, Investigational
CarfentanilCarfentanil may increase the serotonergic activities of Indalpine.Illicit, Investigational, Vet Approved
CarteololThe serum concentration of Carteolol can be increased when it is combined with Indalpine.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Indalpine.Approved, Investigational
CelecoxibIndalpine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Indalpine.Approved, Investigational
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Indalpine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Indalpine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Indalpine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Indalpine.Approved
ChlorothiazideIndalpine may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Indalpine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Indalpine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Indalpine.Approved, Investigational, Withdrawn
ChlorthalidoneIndalpine may increase the hyponatremic activities of Chlorthalidone.Approved
CimetidineThe metabolism of Indalpine can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Indalpine.Approved, Vet Approved
CitalopramIndalpine may increase the serotonergic activities of Citalopram.Approved
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Indalpine.Investigational
ClomipramineIndalpine may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Indalpine.Experimental
CloranololThe serum concentration of Cloranolol can be increased when it is combined with Indalpine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Indalpine.Approved, Illicit
ClorindioneIndalpine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Indalpine.Experimental
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Indalpine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Indalpine.Approved, Illicit
CodeineCodeine may increase the serotonergic activities of Indalpine.Approved, Illicit
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Indalpine.Approved
CyclopenthiazideIndalpine may increase the hyponatremic activities of Cyclopenthiazide.Experimental
CyproheptadineThe therapeutic efficacy of Indalpine can be decreased when used in combination with Cyproheptadine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Indalpine.Approved
DapoxetineDapoxetine may increase the serotonergic activities of Indalpine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Indalpine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Indalpine.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Indalpine is combined with Desmopressin.Approved
DesvenlafaxineDesvenlafaxine may increase the serotonergic activities of Indalpine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Indalpine.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Indalpine.Approved, Vet Approved
DextromethorphanIndalpine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Indalpine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Indalpine.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the serotonergic activities of Indalpine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Indalpine.Approved, Illicit, Vet Approved
DicoumarolIndalpine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Indalpine.Experimental
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Indalpine.Approved, Illicit
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Indalpine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Indalpine.Experimental, Illicit
DiphenadioneIndalpine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Indalpine.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Indalpine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Indalpine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Indalpine.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Indalpine.Approved
DPDPEDPDPE may increase the serotonergic activities of Indalpine.Experimental
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Indalpine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Indalpine.Experimental, Illicit
DuloxetineDuloxetine may increase the serotonergic activities of Indalpine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Indalpine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Indalpine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Indalpine.Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Indalpine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Indalpine.Approved, Investigational, Vet Approved
EpanololThe serum concentration of Epanolol can be increased when it is combined with Indalpine.Experimental
EscitalopramIndalpine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Indalpine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Indalpine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Indalpine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Indalpine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Indalpine.Approved, Illicit, Withdrawn
Ethyl biscoumacetateIndalpine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Indalpine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Indalpine.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Indalpine.Approved, Illicit
EthylmorphineEthylmorphine may increase the serotonergic activities of Indalpine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Indalpine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Indalpine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Indalpine.Approved
EtodolacIndalpine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Indalpine.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Indalpine.Withdrawn
EtoricoxibIndalpine may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Indalpine.Illicit, Vet Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Indalpine.Approved, Illicit, Withdrawn
FenfluramineIndalpine may increase the serotonergic activities of Fenfluramine.Illicit, Investigational, Withdrawn
FentanylFentanyl may increase the serotonergic activities of Indalpine.Approved, Illicit, Investigational, Vet Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Indalpine.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Indalpine.Approved, Illicit
FluindioneIndalpine may increase the anticoagulant activities of Fluindione.Investigational
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Indalpine.Approved, Illicit
FluoxetineIndalpine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Indalpine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Indalpine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Indalpine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Indalpine.Approved, Investigational
FluvoxamineIndalpine may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Indalpine.Approved, Illicit, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Indalpine.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Indalpine.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Indalpine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Indalpine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Indalpine.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Indalpine.Approved, Illicit
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Indalpine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Indalpine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Indalpine.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Indalpine is combined with Harmaline.Experimental
HeroinHeroin may increase the serotonergic activities of Indalpine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Indalpine.Approved
HydrochlorothiazideIndalpine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHydrocodone may increase the serotonergic activities of Indalpine.Approved, Illicit
HydroflumethiazideIndalpine may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneHydromorphone may increase the serotonergic activities of Indalpine.Approved, Illicit
IndapamideIndalpine may increase the hyponatremic activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Indalpine.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Indalpine.Investigational
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Indalpine.Approved, Investigational
Ioflupane I-123Indalpine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproniazidIproniazid may increase the serotonergic activities of Indalpine.Withdrawn
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Indalpine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Indalpine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Indalpine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Indalpine.Approved
KetobemidoneKetobemidone may increase the serotonergic activities of Indalpine.Approved, Investigational
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Indalpine.Approved
LandiololThe serum concentration of Landiolol can be increased when it is combined with Indalpine.Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Indalpine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Indalpine.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Indalpine.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Indalpine.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Indalpine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Indalpine.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Indalpine.Approved, Investigational
LithiumLithium may increase the serotonergic activities of Indalpine.Approved
LofentanilLofentanil may increase the serotonergic activities of Indalpine.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Indalpine.Experimental
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Indalpine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Indalpine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Indalpine.Approved
LumiracoxibIndalpine may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Indalpine.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Indalpine.Approved, Vet Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Indalpine.Experimental
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Indalpine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Indalpine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Indalpine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Indalpine.Approved, Investigational
MepindololThe serum concentration of Mepindolol can be increased when it is combined with Indalpine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Indalpine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Indalpine.Approved, Illicit
MeptazinolMeptazinol may increase the serotonergic activities of Indalpine.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Indalpine.Approved, Investigational
MethadoneThe metabolism of Methadone can be decreased when combined with Indalpine.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Indalpine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Indalpine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Indalpine.Illicit, Withdrawn
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Indalpine.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Indalpine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Indalpine.Approved, Investigational, Vet Approved
MethyclothiazideIndalpine may increase the hyponatremic activities of Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Indalpine.Experimental
Methylene blueIndalpine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Indalpine.Approved
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Indalpine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Indalpine.Approved, Investigational
MetolazoneIndalpine may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Indalpine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Indalpine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Indalpine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Indalpine.Approved, Illicit
MilnacipranMilnacipran may increase the serotonergic activities of Indalpine.Approved
MinaprineMinaprine may increase the serotonergic activities of Indalpine.Approved
MoclobemideMoclobemide may increase the serotonergic activities of Indalpine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Indalpine.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Indalpine.Approved, Investigational, Withdrawn
MorphineMorphine may increase the serotonergic activities of Indalpine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Indalpine.Approved, Investigational
NabumetoneIndalpine may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Indalpine.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Indalpine.Approved
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Indalpine.Approved, Investigational
NefazodoneNefazodone may increase the serotonergic activities of Indalpine.Approved, Withdrawn
NialamideNialamide may increase the serotonergic activities of Indalpine.Withdrawn
NicomorphineNicomorphine may increase the serotonergic activities of Indalpine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Indalpine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Indalpine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Indalpine.Investigational
NormethadoneNormethadone may increase the serotonergic activities of Indalpine.Approved, Illicit
OlanzapineIndalpine may increase the serotonergic activities of Olanzapine.Approved, Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Indalpine.Approved
OpiumOpium may increase the serotonergic activities of Indalpine.Approved, Illicit
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Indalpine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Indalpine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Indalpine.Approved, Investigational
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Indalpine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Indalpine.Approved
OxycodoneOxycodone may increase the serotonergic activities of Indalpine.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the serotonergic activities of Indalpine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Indalpine.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Indalpine.Approved, Investigational
ParecoxibIndalpine may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Indalpine.Approved
ParoxetineIndalpine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Indalpine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Indalpine.Experimental
PentazocinePentazocine may increase the serotonergic activities of Indalpine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Indalpine.Approved, Vet Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Indalpine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Indalpine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Indalpine.Approved
PethidinePethidine may increase the serotonergic activities of Indalpine.Approved
PhenazocinePhenazocine may increase the serotonergic activities of Indalpine.Experimental
PhenelzinePhenelzine may increase the serotonergic activities of Indalpine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Indalpine.Experimental
PhenindioneIndalpine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Indalpine.Approved
PhenoperidinePhenoperidine may increase the serotonergic activities of Indalpine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Indalpine.Approved
PhenprocoumonIndalpine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Indalpine.Approved
PindololThe serum concentration of Pindolol can be increased when it is combined with Indalpine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Indalpine.Approved, Investigational
PiritramidePiritramide may increase the serotonergic activities of Indalpine.Investigational
PirlindolePirlindole may increase the serotonergic activities of Indalpine.Approved
Platelet Activating FactorThe serum concentration of Platelet Activating Factor can be increased when it is combined with Indalpine.Experimental
PolythiazideIndalpine may increase the hyponatremic activities of Polythiazide.Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Indalpine.Approved
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Indalpine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Indalpine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Indalpine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Indalpine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Indalpine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Indalpine is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Indalpine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Indalpine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Indalpine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Indalpine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Indalpine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Indalpine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Indalpine.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Indalpine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Indalpine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Indalpine.Approved, Investigational
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Indalpine.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Indalpine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Indalpine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Indalpine.Approved
QuinethazoneIndalpine may increase the hyponatremic activities of Quinethazone.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Indalpine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Indalpine.Investigational
RasagilineRasagiline may increase the serotonergic activities of Indalpine.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Indalpine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Indalpine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Indalpine.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Indalpine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Indalpine.Investigational
RofecoxibIndalpine may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Indalpine.Vet Approved
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Indalpine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Indalpine.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Indalpine.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Indalpine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Indalpine.Approved, Investigational, Withdrawn
SertralineIndalpine may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Indalpine.Approved, Vet Approved
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Indalpine.Approved
SotalolThe serum concentration of Sotalol can be increased when it is combined with Indalpine.Approved
SufentanilSufentanil may increase the serotonergic activities of Indalpine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Indalpine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Indalpine.Experimental
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Indalpine.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Indalpine.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Indalpine.Investigational
TapentadolTapentadol may increase the serotonergic activities of Indalpine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Indalpine.Approved
TertatololThe serum concentration of Tertatolol can be increased when it is combined with Indalpine.Experimental
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Indalpine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Indalpine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Indalpine.Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Indalpine.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Indalpine.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Indalpine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Indalpine.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Indalpine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Indalpine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Indalpine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Indalpine.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Indalpine.Vet Approved
TilidineTilidine may increase the serotonergic activities of Indalpine.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Indalpine.Approved
TioclomarolIndalpine may increase the anticoagulant activities of Tioclomarol.Experimental
ToloxatoneToloxatone may increase the serotonergic activities of Indalpine.Approved
TramadolIndalpine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Indalpine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Indalpine.Approved
TrazodoneIndalpine may increase the serotonergic activities of Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Indalpine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Indalpine.Vet Approved
TrichlormethiazideIndalpine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Indalpine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Indalpine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Indalpine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Indalpine.Approved, Vet Approved
ValdecoxibIndalpine may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Indalpine.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Indalpine.Approved
VenlafaxineVenlafaxine may increase the serotonergic activities of Indalpine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Indalpine.Experimental
VilazodoneIndalpine may increase the serotonergic activities of Vilazodone.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Indalpine.Experimental
VortioxetineIndalpine may increase the serotonergic activities of Vortioxetine.Approved
WarfarinIndalpine may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Indalpine.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Indalpine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Indalpine.Approved, Illicit, Investigational
ZimelidineIndalpine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Indalpine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Indalpine.Vet Approved
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Indalpine.Approved
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Indalpine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Indalpine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Indalpine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 4,064,255.

General References
  1. Marcin LR, Mattson RJ, Gao Q, Wu D, Molski TF, Mattson GK, Lodge NJ: Synthesis and hSERT activity of homotryptamine analogs. Part 6: [3+2] dipolar cycloaddition of 3-vinylindoles. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1027-30. doi: 10.1016/j.bmcl.2009.12.043. Epub 2009 Dec 16. [PubMed:20034793]
  2. Galbaud du Fort G: [Hematologic toxicity of antidepressive agents]. Encephale. 1988 Jul-Aug;14(4):307-18. [PubMed:3058454]
External Links
PubChem Compound
44668
PubChem Substance
310264918
ChemSpider
40643
BindingDB
50029150
ChEBI
134939
ChEMBL
CHEMBL276520
Wikipedia
Indalpine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)167 U.S. Patent 4,064,255.
Predicted Properties
PropertyValueSource
Water Solubility0.0125 mg/mLALOGPS
logP3.58ALOGPS
logP3.07ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)17.32ChemAxon
pKa (Strongest Basic)10.36ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area27.82 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity71.77 m3·mol-1ChemAxon
Polarizability27.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 3-alkylindoles. These are compounds containing an indole moiety that carries an alkyl chain at the 3-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indoles
Direct Parent
3-alkylindoles
Alternative Parents
Aralkylamines / Substituted pyrroles / Piperidines / Benzenoids / Heteroaromatic compounds / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
3-alkylindole / Aralkylamine / Piperidine / Substituted pyrrole / Benzenoid / Pyrrole / Heteroaromatic compound / Secondary aliphatic amine / Secondary amine / Azacycle
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on May 28, 2014 11:04 / Updated on December 01, 2017 16:11